← Back to Analyst Consensus 
PTHS Buy
Pelthos Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 12, 2026 (17 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | Lake Street | maintain | Buy → Buy | — | 47% |
| Aug 14, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| May 15, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Apr 1, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 20, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Mar 19, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 27, 2026 | Piper Sandler | initiate | — → Overweight | $48 | 54% |
| Feb 26, 2026 | Roth Capital | maintain | Buy → Buy | $55 | 53% |
| Jan 26, 2026 | Oppenheimer | maintain | Outperform → Outperform | $60 | 52% |
| Dec 3, 2025 | Lake Street | initiate | — → Buy | $50 | 47% |
| Dec 3, 2025 | HC Wainwright & Co. | initiate | — → Buy | $60 | 44% |
| Nov 25, 2025 | Roth Capital | initiate | — → Buy | $57 | 53% |
| Nov 14, 2025 | Oppenheimer | reiterate | Outperform → Outperform | $57 | 52% |
| Sep 2, 2025 | Oppenheimer | initiate | — → Outperform | $50 | 52% |
Price Target Trend
Mar 31, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days